The Palo Alto‑based frontier AI firm, which focuses on using its environmentally‑derived evolutionary network (EDEN) to reprogram patients’ cells inside the body, said the new capital will fund the development of more sophisticated, customizable and cost‑effective cell‑based medicines.
EDEN, described by Basecamp as the world’s largest and most diverse evolutionary dataset‑driven model, can design long, complex DNA sequences and pair them with large serine recombinases that insert the sequences precisely into the genome. In pre‑clinical tests the model achieved a 63.2% functional hit rate across diverse DNA prompts and half of its generated large serine recombinases were active in human T cells, delivering therapeutically relevant levels of chimeric antigen receptor insertion.
Basecamp’s co‑founder and CEO, Dr. Glen Gowers, said the company’s goal is to “reprogram the body to repair itself,” adding that the financing brings the technology closer to patients who currently have few treatment options. The firm also highlighted pre‑clinical success across multiple modalities, including a synthetic microbiome covering more than 9,000 species with 99% taxonomic accuracy.
The round attracted a roster of high‑profile investors. Anthropic participated through its $100 million Anthology Fund, which also provides portfolio companies with credits for Anthropic’s Claude models. Nvidia’s venture arm, NVentures, contributed alongside other backers such as S32, Catalio, Firebrand River Capital, The Rockefeller Foundation and the NATO Innovation Fund. S32 led the round, and its partner Andy Conrad, former CEO of Google’s Verily, will join Basecamp’s board.
Basecamp has previously raised $60 million in a Series B earlier this year and $20 million in a Series A two years prior. The latest infusion brings total funding to roughly $220 million and positions the company to expand partnerships with biopharma firms. In April the startup appointed former Biogen executive Richard Pearce as chief business officer to drive those collaborations.
Industry observers see the financing as a signal that AI‑driven therapeutic design is moving from research labs toward commercial pipelines. Roche vice‑chair André Hoffmann, who is also a board member of Genentech and a World Economic Forum co‑chair, praised Basecamp’s platform as the next transformation in biotechnology, noting that the combination of AI, massive biological data and scientific insight could reshape drug discovery and disease understanding.